AbbVie cuts third-quarter guidance. AbbVie stock is valued at USD 510.7 billion

Published on 10/21/2026 at 11:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie cut its outlook to USD 3.73-3.77 after a USD 216 million charge. AbbVie stock costs EUR 256.70 on October 21, 2026 at USD 510.7 billion.

Guidance and earnings dates

AbbVie included a USD 216 million charge in its October 5, 2026 outlook update.
Second-quarter revenue reached USD 16.99 billion on July 31, 2026.
AbbVie stock trades at EUR 256.70 at 11:15 a.m. CEST at Lang & Schwarz on October 21, 2026.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) cut its third-quarter 2026 adjusted earnings-per-share outlook to USD 3.73-3.77 after including a USD 216 million acquired research and development charge. The disclosure dated October 5, 2026 came ahead of the company's scheduled results, while AbbVie stock is valued at USD 510.7 billion.

Guidance falls before results

The filing reduced full-year 2026 adjusted earnings-per-share guidance to USD 13.76-13.96 from USD 13.87-14.07. The same filing said the acquired research and development and milestone expense would reduce both GAAP and adjusted diluted earnings per share by USD 0.11. The SEC filing identified the charge and the revised ranges.

AbbVie had reported second-quarter 2026 revenue of USD 16.99 billion and adjusted earnings per share of USD 3.65 on July 31, 2026, according to MarketBeat. Revenue was USD 16.80 billion in the comparison estimate, creating a USD 0.19 billion revenue beat for that quarter.

What dates matter next?

Chronology puts the latest update in context. On July 31, 2026, AbbVie reported USD 16.99 billion in second-quarter revenue. On October 1, 2026, the company announced its next results date. On October 5, 2026, it set third-quarter adjusted earnings-per-share guidance at USD 3.73-3.77 after the USD 216 million charge. The October 1 release from AbbVie said third-quarter results are due on October 30, 2026, before the US market opens. The company also scheduled an 8 a.m. Central Time earnings call. MarketBeat reported a USD 1.73 quarterly dividend payable on November 16, 2026, to shareholders of record on October 15, 2026.

The central comparison is between the revised outlook and the prior range: the lower end moved from USD 13.87 to USD 13.76 for full-year adjusted earnings per share, while the upper end moved from USD 14.07 to USD 13.96. That USD 0.11 reduction matches the disclosed charge per share.

Stock price and valuation

AbbVie operates in Healthcare and is classified as a general drug manufacturer. Its primary listing is on the New York Stock Exchange under ticker ABBV. The USD 190.75 to USD 291.40 52-week range and USD 510.7 billion market capitalization are dated October 20, 2026.

AbbVie stock was trading at EUR 256.70 at Lang & Schwarz on October 21, 2026 at 11:15 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.